Kornmueller Karin, Amri Ez-Zoubir, Scheideler Marcel, Prassl Ruth
Department of Biophysics, Gottfried Schatz Research Center, Medical University of Graz, Austria.
Université Côte d'Azur, CNRS, Inserm, iBV, France.
Adv Drug Deliv Rev. 2022 Feb;181:114110. doi: 10.1016/j.addr.2021.114110. Epub 2022 Jan 4.
Despite the increasing prevalence of obesity and diabetes, there is no efficient treatment to combat these epidemics. The adipose organ is the main site for energy storage and plays a pivotal role in whole body lipid metabolism and energy homeostasis, including remodeling and dysfunction of adipocytes and adipose tissues in obesity and diabetes. Thus, restoring and balancing metabolic functions in the adipose organ is in demand. MiRNAs represent a novel class of drugs and drug targets, as they are heavily involved in the regulation of many cellular and metabolic processes and diseases, likewise in adipocytes. In this review, we summarize key regulatory activities of miRNAs in the adipose organ, discuss various miRNA replacement and inhibition strategies, promising delivery systems for miRNAs and reflect the future of novel miRNA-based therapeutics to target adipose tissues with the ultimate goal to combat metabolic disorders.
尽管肥胖症和糖尿病的患病率不断上升,但目前尚无有效的治疗方法来应对这些流行病。脂肪器官是能量储存的主要场所,在全身脂质代谢和能量稳态中起着关键作用,包括肥胖症和糖尿病中脂肪细胞和脂肪组织的重塑及功能障碍。因此,恢复和平衡脂肪器官的代谢功能很有必要。微小RNA(miRNA)代表了一类新型药物和药物靶点,因为它们大量参与许多细胞和代谢过程及疾病的调控,在脂肪细胞中亦是如此。在本综述中,我们总结了miRNA在脂肪器官中的关键调控作用,讨论了各种miRNA替代和抑制策略、有前景的miRNA递送系统,并展望了以脂肪组织为靶点的新型基于miRNA疗法的未来,其最终目标是对抗代谢紊乱。